StockWatch: Positive Phase III Data Sells Investors on Intellia (opens in new tab)

A second positive Phase III data readout in two months is a major reason why Intellia Therapeutics shares have soared more than 76% over the past six months—including a 29% surge this past week that followed the CRISPR gene editing therapy developer’s lead pipeline candidate lonvoguran ziclumeran (lonvo-z) meeting three key secondary endpoints in a pivotal study in patients with hereditary angioedema (HAE).